Cargando…
Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients
BACKGROUND AND AIM: Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in different countries. Liver fibrosis is considered as the most appropriate predictor of NAFLD‐associated outcome. Microfibrillar‐associated protein 4 (MFAP4) is a glycoprotein located in the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Publishing Asia Pty Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037036/ https://www.ncbi.nlm.nih.gov/pubmed/36968563 http://dx.doi.org/10.1002/jgh3.12873 |
_version_ | 1784911796257161216 |
---|---|
author | Kanaan, Reine Yaghi, Cesar Saade Riachy, Carole Schlosser, Anders Hamade, Aline Holmskov, Uffe Medlej‐Hashim, Myrna Sørensen, Grith Lykke Jounblat, Rania |
author_facet | Kanaan, Reine Yaghi, Cesar Saade Riachy, Carole Schlosser, Anders Hamade, Aline Holmskov, Uffe Medlej‐Hashim, Myrna Sørensen, Grith Lykke Jounblat, Rania |
author_sort | Kanaan, Reine |
collection | PubMed |
description | BACKGROUND AND AIM: Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in different countries. Liver fibrosis is considered as the most appropriate predictor of NAFLD‐associated outcome. Microfibrillar‐associated protein 4 (MFAP4) is a glycoprotein located in the extracellular matrix. Circulatory MFAP4 has been suggested as a noninvasive biomarker for the assessment of hepatitis C virus and alcoholic liver disease associated liver fibrosis. In this study, we aimed to investigate the association between serum MFAP4 and liver fibrosis severity in NAFLD patients. METHODS: A case–control study was conducted in which NAFLD patients (n = 25) and healthy participants (n = 12) were recruited. Liver fibrosis/cirrhosis was assessed by transient elastography (TE) and biochemical parameters were collected. Serum MFAP4 was measured by sandwich ELISA based on two monoclonal anti‐MFAP4 antibodies and calibrated with a standard of recombinant MFAP4. RESULTS: Serum MFAP4 levels increased with fibrosis severity and were highly upregulated in patients with cirrhosis (F4 fibrosis stage). In addition, serum MFAP4 levels positively correlated with TE measurement and showed significant association with the severely advanced fibrotic stage in NAFLD patients, in multiple linear regression analysis following adjustment for age, gender, and body mass index. CONCLUSION: This study suggests the use of MFAP4 as a potential diagnostic noninvasive biomarker for cirrhosis screening in NAFLD patients. |
format | Online Article Text |
id | pubmed-10037036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wiley Publishing Asia Pty Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-100370362023-03-25 Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients Kanaan, Reine Yaghi, Cesar Saade Riachy, Carole Schlosser, Anders Hamade, Aline Holmskov, Uffe Medlej‐Hashim, Myrna Sørensen, Grith Lykke Jounblat, Rania JGH Open Original Articles BACKGROUND AND AIM: Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in different countries. Liver fibrosis is considered as the most appropriate predictor of NAFLD‐associated outcome. Microfibrillar‐associated protein 4 (MFAP4) is a glycoprotein located in the extracellular matrix. Circulatory MFAP4 has been suggested as a noninvasive biomarker for the assessment of hepatitis C virus and alcoholic liver disease associated liver fibrosis. In this study, we aimed to investigate the association between serum MFAP4 and liver fibrosis severity in NAFLD patients. METHODS: A case–control study was conducted in which NAFLD patients (n = 25) and healthy participants (n = 12) were recruited. Liver fibrosis/cirrhosis was assessed by transient elastography (TE) and biochemical parameters were collected. Serum MFAP4 was measured by sandwich ELISA based on two monoclonal anti‐MFAP4 antibodies and calibrated with a standard of recombinant MFAP4. RESULTS: Serum MFAP4 levels increased with fibrosis severity and were highly upregulated in patients with cirrhosis (F4 fibrosis stage). In addition, serum MFAP4 levels positively correlated with TE measurement and showed significant association with the severely advanced fibrotic stage in NAFLD patients, in multiple linear regression analysis following adjustment for age, gender, and body mass index. CONCLUSION: This study suggests the use of MFAP4 as a potential diagnostic noninvasive biomarker for cirrhosis screening in NAFLD patients. Wiley Publishing Asia Pty Ltd 2023-02-23 /pmc/articles/PMC10037036/ /pubmed/36968563 http://dx.doi.org/10.1002/jgh3.12873 Text en © 2023 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Kanaan, Reine Yaghi, Cesar Saade Riachy, Carole Schlosser, Anders Hamade, Aline Holmskov, Uffe Medlej‐Hashim, Myrna Sørensen, Grith Lykke Jounblat, Rania Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients |
title | Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients |
title_full | Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients |
title_fullStr | Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients |
title_full_unstemmed | Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients |
title_short | Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients |
title_sort | serum mfap4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in nafld patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037036/ https://www.ncbi.nlm.nih.gov/pubmed/36968563 http://dx.doi.org/10.1002/jgh3.12873 |
work_keys_str_mv | AT kanaanreine serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients AT yaghicesar serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients AT saaderiachycarole serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients AT schlosseranders serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients AT hamadealine serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients AT holmskovuffe serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients AT medlejhashimmyrna serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients AT sørensengrithlykke serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients AT jounblatrania serummfap4anovelpotentialbiomarkerforlivercirrhosisscreeningcorrelateswithtransientelastographyinnafldpatients |